Therapeutic Response
ER positive, ERBB2 amplification, and PR negative status confers therapeutic sensitivity to Lapatinib in combination with Trastuzumab in patients with Invasive Breast Carcinoma.
Statements
| Source and description |
|---|
ER positive, ERBB2 amplification, and PR negative status confers therapeutic sensitivity to Lapatinib in combination with Trastuzumab in patients with Invasive Breast Carcinoma.
| Source and description |
|---|